GCG and macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss: This study describes safety, compliance, and changes in quality of life in 11 SBS patients at baseline, week 13, 26, and 52 during two years of subcutaneous GLP-2 treatment, 400 microgram TID, intermitted by an 8-week washout period.Methods.